Dr Reddy’s to distribute Sanofi vaccines in India
Dr Reddy’s Laboratories entered into an exclusive partnership with Sanofi Healthcare India Private Ltd (SHIPL) to promote and distribute Sanofi’s vaccine brands in India.
Hyderabadbased Dr Reddy’s will promote and distribute Sanofi’s paediatric and adult vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U.
These brands registered combined sales of about
The partnership makes Dr Reddy’s the second-biggest vaccine player in India
₹426 crore, as per IQVIA February 2024 estimates. Sanofi will own, manufacture and import these brands into India.
“Vaccine confidence has reached its highest in India in the last few years. Yet, there is much to be done for the rest of the country’s large unvaccinated cohort,” Preeti Futnani, General Manager India for Vaccines, Sanofi, said in a release.
EXPANSION PLANS
“To fulfil our longterm commitment to India and expand our geographic reach, we’re pleased to partner with Dr Reddy’s Laboratories for exclusive distribution and promotion,” Futnani added.
MV Ramana, CEO, Branded Markets (India and
Emerging Markets), Dr Reddy’s, said, “We are happy to have the opportunity to leverage our strengths in promotion and distribution to considerably expand engagement with healthcare professionals and help widen the access of Sanofi’s vaccine brands in India.’’
The portfolio gives Dr Reddy’s a ‘strong’ presence in the vaccine segment, taking it to the second position among vaccine players in India, Ramana said, adding, “Through each product and partnership, our aim is to serve over 1.5 billion patients by 2030.”